Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. Jenzer M, et al. Among authors: hohenfellner m. Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23. Cancer Immunol Immunother. 2019. PMID: 31549213 Free PMC article.
Decoy receptor 3 is a prognostic factor in renal cell cancer.
Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W. Macher-Goeppinger S, et al. Among authors: hohenfellner m. Neoplasia. 2008 Oct;10(10):1049-56. doi: 10.1593/neo.08626. Neoplasia. 2008. PMID: 18813347 Free PMC article.
Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer.
Macher-Goeppinger S, Aulmann S, Tagscherer KE, Wagener N, Haferkamp A, Penzel R, Brauckhoff A, Hohenfellner M, Sykora J, Walczak H, Teh BT, Autschbach F, Herpel E, Schirmacher P, Roth W. Macher-Goeppinger S, et al. Among authors: hohenfellner m. Clin Cancer Res. 2009 Jan 15;15(2):650-9. doi: 10.1158/1078-0432.CCR-08-0284. Clin Cancer Res. 2009. PMID: 19147771
Molecular heterogeneity of TFE3 activation in renal cell carcinomas.
Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P, Aulmann S. Macher-Goeppinger S, et al. Among authors: hohenfellner m. Mod Pathol. 2012 Feb;25(2):308-15. doi: 10.1038/modpathol.2011.169. Epub 2011 Oct 28. Mod Pathol. 2012. PMID: 22037260 Free article.
The centrosome as potential target for cancer therapy and prevention.
Korzeniewski N, Hohenfellner M, Duensing S. Korzeniewski N, et al. Among authors: hohenfellner m. Expert Opin Ther Targets. 2013 Jan;17(1):43-52. doi: 10.1517/14728222.2013.731396. Epub 2012 Oct 15. Expert Opin Ther Targets. 2013. PMID: 23062185 Review.
404 results